Cyclocreatine Phosphate: A Novel Bioenergetic/Anti-Inflammatory Drug That Resuscitates Poorly Functioning Hearts and Protects against Development of Heart Failure
Authors:
- Salwa A. ElgebalySalwa A. Elgebaly
- Charles Van BurenCBCharles Van Buren
- Robert ToddRTRobert Todd
- Robert PostonRPRobert Poston
- Reem K. ArafaRAReem K. Arafa
- Nashwa El-KhazragyNashwa El-Khazragy
- Donald KreutzerDKDonald Kreutzer
- Mostafa A. RabieMRMostafa A. Rabie
- Ahmed F. MohamedAMAhmed F. Mohamed
- Lamiaa A. AhmedLALamiaa A. Ahmed
- Nesrine S. El SayedNSNesrine S. El Sayed
Open Access
- 16 March 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (3) , 453
Abstract
Irreversible myocardial injury causes the exhaustion of cellular adenosine triphosphate (ATP) contributing to heart failure (HF). Cyclocreatine phosphate (CCrP) was shown to preserve myocardial ATP during ischemia and maintain cardiac function in various animal models of ischemia/reperfusion. We tested whether CCrP administered prophylactically/therapeutically prevents HF secondary to ischemic injury in an isoproterenol (ISO) rat model. Thirty-nine rats were allocated into five groups: control/saline, control/CCrP, ISO/saline (85 and 170 mg/kg/day s.c. for 2 consecutive days), and ISO/CCrP (0.8 g/kg/day i.p.) either administrated 24 h or 1 h before ISO administration (prophylactic regimen) or 1 h after the last ISO injection (therapeutic regimen) and then daily for 2 weeks. CCrP protected against ISO-induced CK-MB elevation and ECG/ST changes when administered prophylactically or therapeutically. CCrP administered prophylactically decreased heart weight, hs-TnI, TNF-α, TGF-β, and caspase-3, as well as increased EF%, eNOS, and connexin-43, and maintained physical activity. Histology indicated a marked decrease in cardiac remodeling (fibrin and collagen deposition) in the ISO/CCrP rats. Similarly, therapeutically administered CCrP showed normal EF% and physical activity, as well as normal serum levels of hs-TnI and BNP. In conclusion, the bioenergetic/anti-inflammatory CCrP is a promising safe drug against myocardial ischemic sequelae, including HF, promoting its clinical application to salvage poorly functioning hearts.Keywords
Funding Information
- Academy of Scientific Research and Technology (ASRT), Ministry of Scientific Research, Egypt (ASRT-Jesor 2371, NHI-19-011)
- Nour Heart, Inc. (ASRT-Jesor 2371, NHI-19-011)
This publication has 28 references indexed in Scilit:
- Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusionExpert Review of Cardiovascular Therapy, 2019
- Heart Failure With Preserved Ejection Fraction In PerspectiveCirculation Research, 2019
- The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report—2018; Focus Theme: Multiorgan TransplantationThe Journal of Heart and Lung Transplantation, 2018
- Delayed Care and Mortality Among Women and Men With Myocardial InfarctionJournal of the American Heart Association, 2017
- Mitochondrial function as a therapeutic target in heart failureNature Reviews Cardiology, 2016
- A simple practice guide for dose conversion between animals and humanJournal of Basic and Clinical Pharmacy, 2016
- Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in ratsBiochemical Pharmacology, 2015
- Clinical Features and Outcomes of Takotsubo (Stress) CardiomyopathyNew England Journal of Medicine, 2015
- Functional and Histological Assessment of an Experimental Model of Takotsubo's CardiomyopathyJournal of the American Heart Association, 2014
- Synthesis and accumulation of an extremely stable high-energy phosphate compound by muscle, heart, and brain of animals fed the creatine analog, 1-carboxyethyl-2-iminoimidazolidine (homocyclocreatine)Archives of Biochemistry and Biophysics, 1983